Inogen Q2 EBITDA Beats, Raises Full-Year Guidance on International Demand
INGN is trading near its 52-week low of $5.34 (14% above the low).
Summary
Inogen's Q2 adjusted EBITDA of $2.4M beat consensus by 40%, driven by strong international portable oxygen concentrator demand and favorable FX. Revenue of $95.1M slightly missed estimates, but gross margin improved to 45.5%. The company raised full-year adjusted EBITDA guidance to $4.0M and sees 2026 revenue of $355M-$361M. This follows the Q1 loss and negative EBITDA — the turnaround is gaining traction. U.S. sales remain weak, but distributor traction and product expansion offer a path to recovery.
At the time of this announcement, INGN was trading at $6.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $175.7M. The 52-week trading range was $5.34 to $9.13. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.